Pharma stock engaged in developing, manufacturing, and marketing complex pharmaceutical products for niche therapeutic areas jumped 5 percent in the day’s trade upon posting its Q4FY24 results with a 94 percent jump in Net Profits.
With a market capitalization of Rs. 19,143 Crores, the shares of Natco Pharma Limited were trading at Rs. 1,068 per equity share, up 3.84 percent from its previous day’s close price of Rs. 1,029.20.
Its revenue from operations grew by 19 percent YoY from Rs. 897.9 Crores in Q4FY23 to Rs. 1,068.3 Crores in Q4FY24 and it grew by 41 percent QoQ from Rs. 758.6 Crores in Q3FY24 to Rs. 1,068.3 Crores in Q4FY24. Annually it generated a revenue of Rs. 2,707.1 Crores in FY23 and Rs. 3,998.8 Crores in FY24 indicating a growth of 48 percent YoY.
Its Net Profit grew by 40 percent from Rs. 275.8 Crores in Q4FY23 to Rs. 386.3 Crores in Q4FY24 and it grew by 82 percent QoQ from Rs. 212.7 Crores in Q3FY24 to Rs. 386.3 Crores in Q4FY24. Annually it generated a profit of Rs. 715.3 Crores in FY23 and Rs. 1,388.3 Crores in FY24 indicating a growth of 94 percent YoY.
Natco Pharma Limited is a vertically integrated, research and development-focused pharmaceutical company engaged in developing, manufacturing, and marketing complex products for niche therapeutic areas.
Natco Pharma Limited has a business presence in all three business segments i.e., finished dosage formulations, active pharmaceutical ingredients, and Contract Manufacturing Business.
As for the revenue breakup for Q4FY24, it generates 86 percent of its revenue from Export Formulationtc, Domestic Formulation 5 percent, API 4 Percent, and Other operating and non-operating income 5 percent.
In Q4FY24, the FII/FPI increased their holding in Natco Pharma Limited from 13.72 percent to 16.14 percent by purchasing an additional 2.42 percent stake.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
